logo
Cannabis Use Varies by Pregnancy Status

Cannabis Use Varies by Pregnancy Status

Medscape3 days ago
TOPLINE:
From 2021 to 2023, the use of cannabis increased in nonpregnant women and stayed stable in pregnant women, with smoking being the most common method used by both. Among pregnant women, the use of cannabis was highest during the first trimester.
METHODOLOGY:
Researchers conducted a secondary analysis of US national survey datasets on drug use and health (2021-2023) to examine the use of cannabis among women of reproductive age (unweighted n = 94,225; age, 12-44 years), including 2051 pregnant women.
The primary outcome was the use of cannabis in the past 30 days.
The women were additionally asked about their methods of using cannabis, including smoking, vaping, dabbing, edibles, and other forms.
The use of other substances in the past 30 days and depression status (specifically a major depressive episode) in the past year were also noted.
TAKEAWAY:
The use of cannabis in nonpregnant women increased from 11.3% in 2021 to 13.5% in 2023, with a pooled prevalence of 12.6% (95% CI, 12.2%-13.0%), whereas it declined in pregnant women during the same period, although not significantly.
Smoking was the most common method of cannabis use in both nonpregnant and pregnant women (72.8% and 65.4%, respectively).
Across the study period, the use of cannabis among pregnant women was highest in the first trimester (10.1%) — peaking at 14.2% in 2022 — and declined in the second and third trimesters.
The use of alcohol, tobacco, and illicit drugs in the past 30 days and a major depressive episode in the past year were significantly associated with the use of cannabis in both pregnant and nonpregnant women. Having more than one child was protective against the use of cannabis relative to having no children at home.
IN PRACTICE:
'Public health campaigns should prioritize clear, accessible messaging about risks associated with cannabis use during pregnancy. Healthcare providers should adopt holistic approaches to address co-occurring substance use and mental health conditions while addressing cannabis-related health concerns,' the authors wrote.
SOURCE:
This study was led by Timothy J. Grigsby, PhD, of the Department of Social and Behavioral Health at the University of Nevada in Las Vegas. It was published online on July 01, 2025, in the American Journal of Preventive Medicine.
LIMITATIONS:
The researchers could not establish that certain factors caused increased cannabis use as the survey data were cross-sectional. The sample size for prenatal use of cannabis was small. Women self-reported their pregnancy trimesters and use of cannabis, which may have led to inaccuracies.
DISCLOSURES:
The authors of this study reported having no specific funding or conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Long-Term Rimegepant Use Safe for Migraine Prevention
Long-Term Rimegepant Use Safe for Migraine Prevention

Medscape

time14 minutes ago

  • Medscape

Long-Term Rimegepant Use Safe for Migraine Prevention

TOPLINE: The use of the calcitonin gene-related peptide (CGRP) antagonist rimegepant 75 mg for 52 weeks showed a favorable safety profile and sustained benefits for migraine prevention in a new open-label extension (OLE) study. The treatment was associated with a reduction in monthly migraine days (MMDs), as well as a low frequency of adverse events (AEs) and no significant hepatic safety concerns. METHODOLOGY: The original phase 2/3 multicenter, randomized, double-blind, placebo-controlled trial included adult participants who had 4-18 moderate-to-severe migraine attacks per month. As reported previously, participants who received one tablet of rimegepant 75 mg every other calendar day for 12 weeks had significantly fewer MMDs than those who received matching placebo, meeting the primary endpoint. The treatment phase was then followed by a 52-week OLE period, where safety and tolerability were assessed through AE monitoring, vital signs assessments, physical examinations, ECGs, and laboratory tests, with special attention to hepatic-related AEs. All OLE participants received the active anti-CGRP. Exploratory outcomes during the extension period included the mean reduction in the number of MMDs and the proportion of participants achieving ≥ 50% and 100% reductions in the number of MMDs. TAKEAWAY: Among 603 participants who entered the OLE period, 71% of the participants completed the study; 52% experienced at least one AE, with most deemed to be mild. Only 2% of participants reported serious AEs, none of which were related to the liver or related to the study drug. Treatment-related AEs occurred in 15% of participants, leading to drug discontinuation in 3%. The most common AEs reported were constipation, upper respiratory tract infection, nausea, migraine, increased liver enzymes, and weight gain, although each occurred in ≤ 1% of participants. The hepatic safety profile was favorable, and liver-related AEs were rare. The mean number of MMDs decreased by 6.2 d/mo over the OLE period, with sustained and increasing treatment benefits being observed without a decrease in the effect. The proportion of participants achieving ≥ 50% and 100% reductions in the number of MMDs increased during the extension period. IN PRACTICE: 'This trial found that participants who took rimegepant every other day and as needed (up to one 75 mg tablet a day) experienced a reduction in migraine days and experienced few side effects. Moreover, the treatment benefits of rimegepant increased over a 1-year period without losing effectiveness,' the investigators wrote. SOURCE: This study was led by David Kudrow, MD, California Medical Clinic for Headache, Santa Monica, California. It was published online on June 30 in Headache. LIMITATIONS: Key limitations included the exclusion of participants with extremely frequent headaches (> 18 headache days per month), which limited the generalizability of the findings. The requirement for a consistent ≥ 50% monthly reduction may have underestimated sustained efficacy, post-randomization dropouts may have skewed the OLE sample, the lack of an active comparator may have introduced bias, and participants' awareness of receiving the drug may have affected reporting. Efficacy endpoints were also exploratory, so definitive conclusions on long-term effectiveness could not be drawn. DISCLOSURES: This study was funded by Biohaven Pharmaceuticals. Several investigators reported having financial or employment ties with the funder or other pharmaceutical companies. One investigator also reported being on the editorial board of journals, including Headache. Full details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Senate votes to cut $9 billion from public broadcasting and foreign aid
Senate votes to cut $9 billion from public broadcasting and foreign aid

Yahoo

time24 minutes ago

  • Yahoo

Senate votes to cut $9 billion from public broadcasting and foreign aid

Senate Republicans early Thursday greenlit President Donald Trump's proposal to claw back billions in global health and public media funding, pushing past frustrations within the GOP conference about the White House's transparency during the process. The White House-requested spending cuts narrowly made it through the Senate in a 51-48 vote after GOP Sens. Lisa Murkowski of Alaska and Susan Collins of Maine voted 'no' alongside Democrats. Sen. Tina Smith (D-Minn.) missed the vote, with her staff disclosing Wednesday that she was being kept in the hospital overnight "out of an abundance of caution." Because Senate Republicans made changes to the legislation it will need to bounce back to the House, which is expected to vote on it later Thursday. Trump will need to sign the recissions bill by the end of Friday, otherwise he will be forced to spend the money Congress previously approved. 'What we are talking about is one-tenth of one percent of all federal spending … but it's a step in the right direction and it's the first time we have done anything like this in 35 years,' Majority Leader John Thune (R-S.D.) said early Thursday morning. It marks the first time in decades that a rescissions package has been approved by the Senate. In 2018, the GOP-controlled chamber narrowly blocked a $15 billion request from Trump, after Collins and then-Sen. Richard Burr of North Carolina opposed it. Even though Trump was successful now, however, there was still plenty of drama. To help address a swath of GOP concerns, the administration agreed to drop a $400 million cut to the global AIDS fighting program, PEPFAR, from the original, $9.4 billion proposal. That brought the Senate GOP bill down to roughly $9 billion. Republicans added language vowing that other areas related to food aid, maternal health, malaria and tuberculosis wouldn't be impacted and that certain food assistance programs would be administration also privately vowed to move around other funding to help offset funding cuts to rural public news stations to win over Sen. Mike Rounds (R-S.D). As part of their roughly 12 hour marathon voting session, Republicans also defeated attempts by Democrats, and some of their GOP colleagues, to strip out spending cuts to global health funds, public broadcasting and international disasters. GOP Sens. Mitch McConnell of Kentucky, Collins and Murkowski supported some of these amendments, but they needed more Republicans to join them. Not enough of them did. And McConnell, who had been viewed as likely to oppose the rescissions package, ultimately voted for it on final passage. Murkowski offered one doomed amendment that would have restored most of the money for the Corporation for Public Broadcasting, which largely funds PBS and NPR. Sen. Mark Kelly (D-Ariz.) put forward another amendment originally authored by Collins that would have further reduced the size of the clawback from $9 billion to $6.5 billion. Collins had decided not to offer that amendment herself over questions about whether it would sink the overall bill —and compel the Senate to revert back to original plans to cut $9.4 billion in previously-approved federal funding, which she opposes even more. Yet even as most Republicans voted for the package, several did so only after voicing their displeasure. Though White House budget director Russ Vought provided a 'matrix' of accounts that would be impacted in the closed door Senate lunch, Republicans remained widely frustrated with the Office of Management and Budget, which they felt had not provided sufficient details about the scope of the funding cuts on the table. 'Let's not consider this a precedent,' said Senate Armed Services Committee Chair Roger Wicker (R-Miss.), who said he was supporting the bill 'with reservation.' Wicker added, from the chamber floor, 'if you come back to us again, Mr. Director of the OMB — if you come back to us again from the executive branch — give us the specific amounts and the specific programs that will be cut.' Sen. Thom Tillis (R-N.C.), hours before voting for the package, said, 'I suspect we're going to find out there are some things that we're going to regret. … And I suspect that when we do we'll have to come back and fix it.' Hanging over Republicans in consideration of the bill was a dual political threat. First, Vought has been flirting with trying to leapfrog Congress altogether on spending cuts by challenging the Impoundment Control Act. The 1974 law prevents the executive branch from pulling back federal funding that's already been appropriated, but Vought has questioned its constitutionality. Rejecting the $9 billion rescissions request could have exacerbated this tension between Republicans and the administration. Second, Trump's GOP allies were also openly warning the president would become incensed if Congress failed to enact a major priority, opening up a political breach with the party's standard-bearer heading into a crucial government funding fight this fall. Trump had gone so far as to warn he would not endorse Republicans who voted against it. That wasn't enough to win over every Republican, though. Collins, who chairs the Senate Appropriations Committee, singled out OMB for not providing enough information when she announced her opposition. She said in a statement that the rescissions package 'has a big problem – nobody really knows what program reductions are in it.' Murkowski, meanwhile, said Congress should be 'doing more when it comes down to our own authorities, our constitutional authorities, when it comes to the power of the purse.' Democrats, and some Republicans, have also warned that passing a rescissions package largely along party lines undercuts their larger government funding talks, where they will likely need bipartisan support to get even a short-term funding patch through the Senate. The Senate Appropriations Committee has advanced two bills and are expected to vote on two more Thursday: a measure to fund Department of Veterans' Affairs as well as the legislation to fund activities within the Departments of Commerce and Justice, which was derailed last week over a fight around funding for relocating the FBI headquarters. 'Republicans are putting a blindfold over their own eyes and leading rural Americans off a cliff, just to make Donald Trump and his billionaire friends happy,' Senate Minority Leader Chuck Schumer (D-N.Y.) said Wednesday. 'Well, Democrats are not here to merely rubber stamp whatever Donald Trump does, just like the Republicans are doing.' Schumer sent a letter to Senate Democrats earlier this month warning that Republicans should not bank on Democrats supporting the larger government funding effort if GOP senators vote to approve the Trump-requested cuts. Democratic senators are already under enormous pressure from their base to not agree to a funding deal negotiated only by Republicans — even a short-term funding patch — after their leadership faced a whirlwind of backlash earlier this year for paving the way for passage of a GOP-negotiated continuing resolution. 'It will become hard, maybe even impossible, to write a bipartisan budget ever again, because the minority party knows they can get double crossed,' said Sen. Chris Murphy (D-Conn.). He warned his GOP colleagues they should expect Democrats to use rescissions in a similar way: 'Democrats will do it to you when we are back in charge.' Jennifer Scholtes contributed to this report.

Clearwater Residents: Experience the Future of Dental Implants
Clearwater Residents: Experience the Future of Dental Implants

Yahoo

time43 minutes ago

  • Yahoo

Clearwater Residents: Experience the Future of Dental Implants

CLEARWATER, Fla., July 17, 2025 /PRNewswire/ -- Britten Periodontics & Implant Dentistry is excited to announce the arrival of cutting-edge advancements in dental implant prosthetics. Clearwater residents can now benefit from more durable, comfortable, and natural-looking solutions for replacing missing teeth. We've incorporated the latest technology to create a truly superior implant experience. Take the first step towards a confident, healthy smile! Schedule your consultation today by visiting or calling us directly. Our friendly team is ready to answer your questions and help you begin your journey to a complete smile. "We're thrilled to be at the forefront of dental innovation here in Clearwater!," said Dr. Todd Britten. "By incorporating 3D-imaging and custom design into our implant procedures, we're providing a level of precision and personalization previously unavailable. This translates to a more comfortable and aesthetically pleasing outcome for our patients, ultimately boosting their confidence and quality of life." These innovative prosthetics utilize 3D-Cone Beam and Digital Scans and custom-designed abutments. This personalized approach ensures a more precise and comfortable fit, leading to improved longevity and a more natural-looking result. The enhanced precision of 3D imaging allows for a more accurate representation of the jawbone, resulting in a more stable and secure implant. The custom abutments are designed to seamlessly integrate with the surrounding teeth, creating a natural and aesthetically pleasing outcome. The benefits extend beyond just aesthetics. Our new prosthetics offer: Enhanced Durability: The advanced materials and precise manufacturing techniques result in implants that are built to last. Superior Comfort: The personalized fit minimizes discomfort and irritation, ensuring a more pleasant experience for patients. Natural Appearance: The seamless integration of the implant with the surrounding teeth provides a truly natural-looking smile. Improved Longevity: The combination of superior materials and precise fit contributes to longer-lasting implants. Britten Periodontics is a premier periodontal and dental implant practice dedicated to delivering exceptional care in a compassionate and professional environment. Located in Clearwater, Florida, our team specializes in the prevention, diagnosis, and treatment of periodontal disease, as well as advanced dental implant procedures. Led by Dr. Todd Britten, a board-certified periodontist, our practice combines state-of-the-art technology with a personalized approach to help patients achieve optimal oral health. For more information, visit View original content to download multimedia: SOURCE Todd M Britten, DMD, LLC.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store